HCPCS Level II code J1560 denotes an intramuscular administration of gamma globulin in volumes greater than 10 cc. This code captures a specific formulation and route of immunoglobulin therapy that is distinct from intravenous preparations and smaller-volume intramuscular injections. It matters nationally because immunoglobulin therapies are used in a range of immune deficiency and autoimmune indications, and clarity in coding supports accurate billing, coverage determinations, and utilization tracking.

Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of payer coverage patterns, common billing modifiers applied to injectable therapies, and the clinical administration context for intramuscular gamma globulin. The publication summarizes national benchmarks for coding frequency and allowed services where available, highlights relevant policy considerations affecting reimbursement and prior authorization, and provides clinical context to distinguish J1560 from other immunoglobulin administration codes.

The content is organized to help billing managers, compliance officers, and policy analysts understand how J1560 is used, what typical sites of service are, and what to expect from major payers. Data not available in the input is noted where applicable.